FDA Approves Daiichi-Sankyo's Azor to Lower Hypertension
Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents.
Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk.
AZOR is a prescription drug used for the treatment of hypertension or high blood pressure. AZOR contains two different active ingredients in one tablet, namely amlodipine and olmesartan medoxomil.
AZOR may be used either alone or in combination with other drugs to treat high blood pressure.
AZOR is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Daiichi Sankyo, Inc. announced that the United States Food and Drug Administration (FDA) has approved AZOR(TM) (amlodipine and olmesartan medoxomil) for the treatment of hypertension, also known as high blood pressure. AZOR is a convenient, once daily, single tablet combination of amlodipine, the number one prescribed calcium channel blocker (CCB) on the market, and olmesartan medoxomil, the active ingredient in Benicar(R), which is the fastest growing angiotensin receptor blocker (ARB). The combination of these two medications will give doctors a powerful new treatment option for patients with hypertension who need to reduce their blood pressure levels or who are uncontrolled on other medications.
In the fight against cardiovascular complications, drug makers across the world are developing new and innovative prescription medications. For some, the use of existing drugs, slightly modified, can be applied to the use of cardiovascular complications.
Azor, provided by Daiichi Sankyo, Inc., has obtained approval for use in the treatment of high blood pressure. Lending its success to the control of high blood pressure where other medications have not proven effective. Using a combination of a calcium channel blocker, with olmesartan medoxomil, individuals who utilize Azor are experiencing significant control of hypertension, also known has high blood pressure.